Author

Fabio Salvatore Macaluso

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN BIOLOGIC-NAïVE PATIENTS: REAL-WORLD DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN BIOLOGIC-NAïVE PATIENTS: REAL-WORLD DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)

Fabio Salvatore Macaluso  et al.

SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501
SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501

Fabio Salvatore Macaluso  et al.

REDUCED HUMORAL RESPONSE TO TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE-IBD, AN IG-IBD STUDY
REDUCED HUMORAL RESPONSE TO TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE-IBD, AN IG-IBD STUDY

Fabio Salvatore Macaluso  et al.

VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE
VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE

Fabio Salvatore Macaluso  et al.

SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)
SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

Fabio Salvatore Macaluso  et al.

EFFECTIVENESS OF USTEKINUMAB ON CROHN´S DISEASE ASSOCIATED SPONDYLOARTROPATHY
EFFECTIVENESS OF USTEKINUMAB ON CROHN´S DISEASE ASSOCIATED SPONDYLOARTROPATHY

Fabio Salvatore Macaluso  et al.

SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2: FINAL RESULTS
SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2: FINAL RESULTS

Fabio Salvatore Macaluso  et al.

VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE
VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE

SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)
SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

REDUCED HUMORAL RESPONSE TO TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE-IBD, AN IG-IBD STUDY
REDUCED HUMORAL RESPONSE TO TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE-IBD, AN IG-IBD STUDY

EFFECTIVENESS AND SAFETY OF NER1006 VERSUS STANDARD BOWEL PREPARATIONS: A META-ANALYSIS OF THREE RANDOMISED PHASE-3 CLINICAL TRIALS
EFFECTIVENESS AND SAFETY OF NER1006 VERSUS STANDARD BOWEL PREPARATIONS: A META-ANALYSIS OF THREE RANDOMISED PHASE-3 CLINICAL TRIALS

Fabio Salvatore Macaluso  et al.

SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)
SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)

Fabio Salvatore Macaluso  et al.

EFFECTIVENESS AND TOLERABILITY OF 1L PEG-ASC PREPARATION FOR COLONOSCOPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
EFFECTIVENESS AND TOLERABILITY OF 1L PEG-ASC PREPARATION FOR COLONOSCOPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Fabio Salvatore Macaluso  et al.

EFFECTIVENESS AND SAFETY OF ON-DEMAND FERRIC CARBOXYMALTOSE INFUSION STRATEGY FOR IRON DEFICIENCY ANEMIA IN INFLAMMATORY BOWEL DISEASE PATIENTS
EFFECTIVENESS AND SAFETY OF ON-DEMAND FERRIC CARBOXYMALTOSE INFUSION STRATEGY FOR IRON DEFICIENCY ANEMIA IN INFLAMMATORY BOWEL DISEASE PATIENTS

Fabio Salvatore Macaluso  et al.

SARCOPENIA IS A POOR PROGNOSTIC FACTOR FOR ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN’S DISEASE
SARCOPENIA IS A POOR PROGNOSTIC FACTOR FOR ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN’S DISEASE

Fabio Salvatore Macaluso  et al.

BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN’S PATIENTS ON BIOLOGICS: A PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES
BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN’S PATIENTS ON BIOLOGICS: A PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES

Fabio Salvatore Macaluso  et al.

Item 1 - 16 / 16
1